Drug General Information
Drug ID
D0OA5G
Former ID
DCL000006
Drug Name
SNS-314
Synonyms
AK2; SN-314
Drug Type
Small molecular drug
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 1 [522092]
Therapeutic Class
Anticancer Agents
Company
Sunesis Pharma
Structure
Download
2D MOL

3D MOL

Formula
C18H15ClN6OS2
Canonical SMILES
C1=CC(=CC(=C1)Cl)NC(=O)NC2=NC=C(S2)CCNC3=NC=NC4=C3SC=C4
InChI
1S/C18H15ClN6OS2/c19-11-2-1-3-12(8-11)24-17(26)25-18-21-9-13(28-18)4-6-20-16-15-14(5-7-27-15)22-10-23-16/h1-3,5,7-10H,4,6H2,(H,20,22,23)(H2,21,24,25,26)
InChIKey
FAYAUAZLLLJJGH-UHFFFAOYSA-N
CAS Number
CAS 1057249-41-8
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Aurora protein kinase Target Info Inhibitor [537044], [537212], [537234], [537635]
Aurora kinase A Target Info Inhibitor [537044], [537212], [537234], [537635]
Aurora kinase B Target Info Inhibitor [537044], [537212], [537234], [537635]
KEGG Pathway Oocyte meiosishsa04114:Oocyte meiosis
Pathway Interaction Database Aurora B signaling
Signaling by Aurora kinases
Integrin-linked kinase signaling
PLK1 signaling events
Aurora A signalingaurora_b_pathway:Aurora B signaling
Aurora C signaling
FOXM1 transcription factor network
Aurora A signaling
Reactome APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
Separation of Sister Chromatids
Resolution of Sister Chromatid Cohesion
RHO GTPases Activate ForminsR-HSA-174178:APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
Regulation of PLK1 Activity at G2/M TransitionR-HSA-174178:APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
RHO GTPases Activate Formins
Mitotic Prometaphase
WikiPathways EGF/EGFR Signaling Pathway
JAK/STAT
Gastric Cancer Network 1
Integrated Breast Cancer Pathway
APC/C-mediated degradation of cell cycle proteinsWP437:EGF/EGFR Signaling Pathway
APC/C-mediated degradation of cell cycle proteinsWP2757:Mitotic Metaphase and Anaphase
Mitotic Prometaphase
Regulation of Microtubule Cytoskeleton
miR-targeted genes in lymphocytes - TarBase
miR-targeted genes in epithelium - TarBase
APC/C-mediated degradation of cell cycle proteins
References
Ref 522092ClinicalTrials.gov (NCT00519662) Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 537044Water-soluble prodrugs of an Aurora kinase inhibitor. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1409-12. Epub 2009 Jan 19.
Ref 537212Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Jan-Feb;31(1):47-57.
Ref 537234The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. Mol Cancer Ther. 2009 Apr;8(4):930-9.
Ref 537635SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol. 2009 Aug 1.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.